Lung Cancer in the US

Lung cancer is the leading cause of cancer death among both men and women in the US.

In 2018, it is estimated that

- 25% of all cancer deaths in 2018
- More than breast, prostate, and colon cancers combined

In 2018, it is estimated that

- 234,030 new cases of lung cancer will be diagnosed
- 154,050 deaths from lung cancer will occur

KEY SUBSETS

Approximately 80%-85% of all lung cancers in the US are non-small cell lung cancer (NSCLC).

There are 3 main types of NSCLC:
- Adenocarcinoma
- Squamous cell carcinoma
- Large cell carcinoma

Approximately 55% of NSCLC cases are adenocarcinoma.

Approximately 23% of adenocarcinomas have EGFR mutations, which are one of the most common mutations.

With five-year survival rates remaining at less than 15% in patients with adenocarcinoma, there has never been a better time to help address the strong medical need.

PERSONALIZED MEDICINE

Personalized medicine means treating each patient based on the characteristics of their disease.

Doctors may use biomarker tests to identify genetic information, such as gene mutations in patients.

Identifying gene mutations can inform doctors and help guide treatment decisions for specific patients.

When it comes to treatment, one size does not fit all.

Personalized medicines are enabling doctors to treat the right patients with the right medicines at the right time, with the goal of changing survival outcomes.

REFERENCES